Research paper | 06-February-2018
Eltoprazine, a drug that had previously been developed for aggression, has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson´s disease (PD) and in dyskinetic PD patients. Much less is known about effects of eltoprazine in other therapeutic indications. Indeed, the pharmacological profile of eltoprazine might suggest its effects on anxiety and food intake, but also adverse effect potential, which is the focus of the present study.
Given for 2 weeks either as
Andreas Gravius,
Andrzej Dekundy,
Anita Vanaga,
Lutz Franke,
Wojciech Danysz
Acta Neurobiologiae Experimentalis, Volume 77 , ISSUE 1, 77–85